Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8301)
All Articles published online
|
Publishing Process of This Article
|
Apr 7, 2017 (publication date) through Jul 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(13): 2448-2452 [PMID: 28428725 DOI: 10.3748/wjg.v23.i13.2448] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v23/i13/2448.htm |
| Number | Citing Articles |
| 1 |
Francesco Tovoli, Stefania De Lorenzo, Maria Aurelia Barbera, Ingrid Garajova, Giorgio Frega, Andrea Palloni, Maria Abbondanza Pantaleo, Guido Biasco, Giovanni Brandi. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. Future Oncology 2017; 13(21): 1893 doi: 10.2217/fon-2017-0166
|
| 2 |
Jordi Bruix, Leonardo G. da Fonseca, María Reig. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology 2019; 16(10): 617 doi: 10.1038/s41575-019-0179-x
|
| 3 |
Sebastião N. Martins-Filho, Venâncio Avancini Ferreira Alves. The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review. Surgical and Experimental Pathology 2019; 2(1) doi: 10.1186/s42047-019-0047-6
|
| 4 |
Weihao Kong, Jun Zheng, Liang Chen, Xiaomin Zuo, Hengyi Wang, Xingyu Wang, Jia Yao, Wei Chen. Mean Corpuscular Hemoglobin Concentration Correlates with Prognosis of Resected Hepatocellular Carcinoma. Biomarkers in Medicine 2020; 14(4): 259 doi: 10.2217/bmm-2019-0224
|
| 5 |
Francesco Paolo Russo, Angela Imondi, Erica Nicola Lynch, Fabio Farinati. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Digestive and Liver Disease 2018; 50(7): 640 doi: 10.1016/j.dld.2018.03.014
|
| 6 |
Nicola Personeni, Tiziana Pressiani, Lorenza Rimassa. Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Science Reports 2020; 3(1) doi: 10.1002/hsr2.147
|
| 7 |
Chiara C. Volpi, Ambra V. Gualeni, Filippo Pietrantonio, Emanuela Vaccher, Antonino Carbone, Annunziata Gloghini. Bright-fieldin situhybridization detects gene alterations and viral infections useful for personalized management of cancer patients. Expert Review of Molecular Diagnostics 2018; 18(3): 259 doi: 10.1080/14737159.2018.1440210
|
| 8 |
Amit G. Singal, Yujin Hoshida, David J. Pinato, Jorge Marrero, Jean-Charles Nault, Valerie Paradis, Nabihah Tayob, Morris Sherman, Young Suk Lim, Ziding Feng, Anna S. Lok, Jo Ann Rinaudo, Sudhir Srivastava, Josep M. Llovet, Augusto Villanueva. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021; 160(7): 2572 doi: 10.1053/j.gastro.2021.01.233
|
| 9 |
María Reig, Leonardo Gomes da Fonseca, Sandrine Faivre. New trials and results in systemic treatment of HCC. Journal of Hepatology 2018; 69(2): 525 doi: 10.1016/j.jhep.2018.03.028
|